EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease

Menghan Gao, Dongwei Kang iD, Na Liu iD, Yanna Liu iD

Molecules · 2023

DOI: 10.3390/molecules28145320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Menghan Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Science…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academic Promotion Program of Shandong First Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic has caused severe health threat globally, and novel SARS-Cov-2 inhibitors are urgently needed for antiviral treatment. The main protease (Mpro) of the virus is one of the most effective and conserved targets for anti-SARS-CoV-2 drug development. In this study, we utilized a molecular docking-based virtual screening approach against the conserved catalytic site to identify small-molecule inhibitors of SARS-CoV-2 Mpro. Further biological evaluation helped us identify two compounds, AF-399/40713777 and AI-942/42301830, with moderate inhibitory activity. Besides that, the in silico data, including molecular dynamics (MD) simulation, binding free energy calculations, and AMDET profiles, suggested that these two hits could serve as the starting point for the future development of COVID-19 intervention treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2Molecular Docking SimulationPandemicsProtease InhibitorsAntiviral AgentsMolecular Dynamics SimulationCoronavirus 3C Proteases

Stichwörter der Autor:innen

MD simulationSARS-CoV-2main protease inhibitorsmolecular docking-based virtual screening

Substanzen

Protease InhibitorsAntiviral Agents3C-like proteinase, SARS-CoV-2Coronavirus 3C Proteases

Autor:innen und Institutionen

  • School of Pharmacy and Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, 6699 Qingdao Road, Jinan 250117, China.
  • NHC Key Laboratory of Biotechnology Drugs, Shandong Academy of Medical Sciences, 6699 Qingdao Road, Jinan 250117, China.
  • Key Lab for Rare & Uncommon Diseases of Shandong Province, 6699 Qingdao Road, Jinan 250117, China.
  • Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan 250012, China.

ORCID-Profile: Dongwei Kang, Na Liu, Yanna Liu

Förderung

  • Academic Promotion Program of Shandong First Medical University

Zitieren

APA

Gao, M., Kang, D., Liu, N., & Liu, Y. (2023). In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease. Molecules. https://doi.org/10.3390/molecules28145320

Vancouver

Gao M, Kang D, Liu N, Liu Y. In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease. Molecules. 2023. doi:10.3390/molecules28145320

BibTeX
@article{Gao2023,
  author = {Gao, Menghan and Kang, Dongwei and Liu, Na and Liu, Yanna},
  title = {In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28145320}
}
Kostenlos starten →